AAV
Gene Therapy at a Crossroads: Rethinking AAV Amid Industry Resets
Daniel Smith, Ph.D.
Nice Consulting
PAO-05-25-NI-02May 06, 2025
Collaboration
Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing
Vertex
PR-M04-21-024Apr 22, 2021
Gene Editing
Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies
Vertex
PR-M06-20-NI-017Jun 12, 2020
Cell and Gene Therapy
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Vertex
PR-M11-19-NI-023Nov 20, 2019
Agreement
Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)
Vertex
PR-M09-19-NI-041Sep 16, 2019
M&A
Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes
Vertex
PR-M09-19-NI-008Sep 04, 2019
Leadership
Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman and Dr. Reshma Kewalramani Appointed as New CEO
Vertex
PR-M07-19-NI-076Jul 29, 2019
FDA Approval
FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease
Vertex
PR-M08-18-NI-075Aug 20, 2018
Research
BNBuilders Completes Construction on Vertex Pharmaceuticals Research Center in San Diego
BNBuilders
PR-M06-18-NI-082Jun 26, 2018